ReCode Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Monday, January 10, 2022
Information
Tags: 
Biotechnology, Health, Genetics, Stem Cells, Pharmaceutical, Liver, SORT, Patient, LNP, Therapy, Tissue, Primary ciliary dyskinesia, Twitter, Conference, Company, Recode, Cystic fibrosis, B cell, LinkedIn, Vaccine
⚠ generated by AI ↴
Organisation: 
RECODE THERAPEUTICS
Summary
Key Points: 
  • ReCode Therapeutics (the Company), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.
  • The presentation will be accessible to registered conference attendees.
  • ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver.
  • The Companys pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia.


ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.

  • Presentation details:

    Date: Thursday, January 13, 2022

    Time: 9:00 a.m. – 9:25 a.m. ET

    Presenter: David Lockhart, Ph.D., President & Chief Scientific Officer

The presentation will be accessible to registered conference attendees.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

Copyright: 
Copyright Business Wire 2022